Kenvue Stock Drops as Neutrogena Faces Boycott Following Hayden Panettiere's Death

2026-08-19 companies

New York, Wednesday, 19 August 2026.
Kenvue shares fell over two percent following public outcry over allegations that Neutrogena dropped the late Hayden Panettiere for speaking about postpartum depression, wiping $787 million from its market value.

Market Reaction and Financial Fallout

On Monday, August 17, 2026, shares of Kenvue Inc. (NYSE: KVUE) slid 2.14% to close at $18.79 [1]. This sudden drop wiped approximately $787 million from the consumer health giant’s market value, with 19.4 million shares changing hands during the trading session [1]. Simultaneously, Kimberly-Clark Corp. (NYSE: KMB), which is in the process of acquiring Kenvue, saw its stock decline by 2.25% to close at $107.91 [1]. The next day, August 18, 2026, Kenvue shares experienced a minor recovery, closing up by $0.01 at $18.80 on a volume of 25.5 million shares [1], representing a marginal daily gain of 0.053 percent, while Kimberly-Clark shares slipped further by 0.18% to close at $107.72 [1].

Neutrogena’s Weight in Kenvue’s Portfolio

Kenvue operates as the world’s largest pure-play consumer health company, employing 22,000 people and generating more than $15 billion in annual revenue [8]. On August 6, 2026, Kenvue reported its second-quarter financial results, posting net sales of $3.96 billion [1]. Within its portfolio, the Skin Health and Beauty segment—where Neutrogena stands as the largest brand—contributed $1.11 billion to total sales [1]. This segment had been showing positive momentum prior to the controversy, registering a net sales growth of 5.1% and organic growth of 3.7% [1]. However, the burgeoning boycott threatens to disrupt this key revenue driver, as consumer sentiment shifts rapidly [1][3].

The Origin of the Backlash

The public outcry was triggered by the tragic death of 36-year-old actress Hayden Panettiere on August 16, 2026, in Greenville, South Carolina [1][6]. While the Greenville County Coroner’s Office confirmed there were no signs of trauma or foul play [1], her passing immediately reignited intense scrutiny over her past relationship with Neutrogena [3][4]. Panettiere, who served as a prominent brand ambassador for the skincare line for roughly a decade [1][6], had detailed a contentious split with the company in her May 2026 memoir, This Is Me: A Reckoning, and during her subsequent book tour [1][4].

Postpartum Depression and the Morals Clause

According to Panettiere’s accounts, which she shared during a May 2026 appearance on Jay Shetty’s On Purpose podcast, Neutrogena attempted to terminate her contract immediately after she spoke openly about her struggles with postpartum depression during a 2015 interview on Live with Kelly and Michael [2][4]. Panettiere had described her postpartum experience as “completely uncontrollable, and it’s really painful, and it’s really scary” [6], urging that “women need a lot of support” [4][6]. She alleged that Neutrogena executives claimed she violated the “morals clause” in her endorsement contract by discussing her mental health [2][4]. Although her agent successfully fought the immediate termination, the brand chose not to renew her contract when it expired in 2016 [2][5].

Viral Boycott Campaigns and Corporate Silence

Following Panettiere’s death, social media platforms were flooded with calls to boycott Neutrogena under hashtags like #BoycottNeutrogena and #JusticeForHayden [2]. A boycott thread on Reddit quickly amassed thousands of upvotes [1][6], while a single post on X generated 1.1 million views and 39,000 likes [1]. Activists are encouraging consumers to hit Kenvue where it hurts by boycotting its entire brand portfolio, including household names like Band-Aid, Tylenol, and Zyrtec [2][4]. Despite the escalating backlash and inquiries from major media outlets, Kenvue and Neutrogena have remained silent and declined to comment [3][5], a strategy that communications experts warn is drawing further criticism [3].

Strategic Implications for the Pending Merger

The timing of this reputational crisis is highly sensitive for Kenvue, which is currently preparing for a major corporate transition [1][8]. On November 2, 2025, Kimberly-Clark agreed to acquire Kenvue for an enterprise value of approximately $48.7 billion [1]. Under the agreed terms, each Kenvue share will convert into 0.14625 Kimberly-Clark shares plus $3.50 in cash [1]. Some market observers have noted the irony of the boycott, pointing out that Neutrogena was owned by Johnson & Johnson during Panettiere’s ambassadorship before being spun off into Kenvue in May 2023 [7][8]. Nevertheless, with Kenvue CEO Kirk Perry previously stating on August 6, 2026, that the merger is expected to close in the fourth quarter of 2026 [1], investors are watching closely to see if the controversy will impact the finalization of the deal [1].

Sources

Consumer sentiment Kenvue stock